A leading paediatric health centre, the Montreal Children’s Hospital is home to a world-renowned team of specialists. The Fondation’s support allows it to finance an exceptional care and research environment serving young patients within the Réseau universitaire intégré de santé et de services sociaux (RUISSS) McGill, which covers 63% of Quebec’s territory, including Montreal, the Montérégie region and several other regions of Quebec.
the Centre is recognized in the treatment of leukemia, lymphoma and solid tumours, as well as in neuro-oncology and cellular therapy. It has also carved out a speciality niche in cancer predisposition syndromes.
Member of the Children’s Oncology Group (COG), the world’s largest research organization, the institution collaborates with the most prestigious networks (FDA, NIH) to ensure rigorous oversight of clinical trials.
Under the direction of international-calibre researchers, leading-edge studies aim to transform lab-based discoveries into concrete treatments that improve clinical outcomes and help overcome disease.
This new five-year commitment of $17,237,335 to the Montreal Children’s Hospital will be invested in accelerating discoveries in paediatric oncology through cutting-edge approaches such as genetics, artificial intelligence and data analysis, while helping to train the next generation of highly specialized experts.
Through this major commitment, the Fondation Charles-Bruneau reaffirms its deep conviction: curing more children, and curing them better, depends on lasting collaboration and research driven by the real needs of children and their families.
“By supporting our research project, the Fondation Charles-Bruneau brings us closer to our ultimate objective: a world where no child has to deal with cancer.”
